Huang Dai compound in treatment of acute promyelocytic leukemia 204 cases of lessons learned.docVIP

 PAGE \* MERGEFORMAT 6 Huang Dai compound in treatment of acute promyelocytic leukemia 204 cases of lessons learned [Keywords:] leukemia, myelocytic, acute; clinical experience; realgar; Qingdai Acute promyelocytic leukemia (acute promyelocytic leukemia, APL) is a special type of acute leukemia, the clinical features of infection for the vulnerable, bleeding and disseminated intravascular coagulation (disseminated intravascular coagulation, DIC) and other complications, death a higher rate. Professor Huang Shilin After graduating from Beijing Traditional Chinese Medicine, more than 40 years, mainly engaged in Chinese medicine clinical and experimental hematology research, has been in the clinical front-line work in the treatment of hematological diseases, has done some work on the more, especially in the treatment of leukemia research accomplishments deep, its evil to attack Qudu theoretical guidance for the development of the compound set of square yellow Dai tablets to treat APL achieved good effect. 1 Data and methods 1.1 Case of 1.1.1 In general From July 1988 to January 2005, Dalian People’s Liberation Army No. 210 Hospital, Chinese Medicine Hematology 204 cases of patients admitted to hospital, such as peripheral blood and bone marrow examination are in line with the United States in 1985, France   British Cooperative Group proposed diagnostic criteria for classification of acute leukemia standard of acute non-lymphocytic leukemia-M3 (acute myelocytic leukemia  M3, AML  M3) diagnostic criteria [1]. 115 cases were male, female 89 cases. Age 5 to 72 years, with a median age of 32.5 years. 1.1.2 pre-hospital treatment of The first time in patients treated with 161 cases, 43 patients re-treated. Re-treated patients after chemotherapy or all-trans retinoic acid (all  trans  retinoic acid, ATRA) has not obtained complete remission after treatment (complete remission, CR) in 24 patients after chemotherapy or relapse after ATRA treatment acces